AU2007244955B2 - Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 - Google Patents

Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 Download PDF

Info

Publication number
AU2007244955B2
AU2007244955B2 AU2007244955A AU2007244955A AU2007244955B2 AU 2007244955 B2 AU2007244955 B2 AU 2007244955B2 AU 2007244955 A AU2007244955 A AU 2007244955A AU 2007244955 A AU2007244955 A AU 2007244955A AU 2007244955 B2 AU2007244955 B2 AU 2007244955B2
Authority
AU
Australia
Prior art keywords
compound
dichloro
alkyl
pyrrolidin
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007244955A
Other languages
English (en)
Other versions
AU2007244955A1 (en
Inventor
Julie Kay Bush
Marvin Martin Hansen
Renhua Li
Thomas Edward Mabry
Nancy June Snyder
Owen Brendan Wallace
Yanping Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38564359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007244955(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2007244955A1 publication Critical patent/AU2007244955A1/en
Application granted granted Critical
Publication of AU2007244955B2 publication Critical patent/AU2007244955B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/50—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2007244955A 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 Ceased AU2007244955B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74547506P 2006-04-24 2006-04-24
US60/745,475 2006-04-24
PCT/US2007/067182 WO2007127688A2 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Publications (2)

Publication Number Publication Date
AU2007244955A1 AU2007244955A1 (en) 2007-11-08
AU2007244955B2 true AU2007244955B2 (en) 2011-12-08

Family

ID=38564359

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007244955A Ceased AU2007244955B2 (en) 2006-04-24 2007-04-23 Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Country Status (32)

Country Link
US (1) US8153807B2 (enExample)
EP (1) EP2021336B1 (enExample)
JP (1) JP5269765B2 (enExample)
KR (1) KR101059614B1 (enExample)
CN (1) CN101432275B (enExample)
AT (1) ATE472542T1 (enExample)
AU (1) AU2007244955B2 (enExample)
BR (1) BRPI0710467A2 (enExample)
CA (1) CA2646624C (enExample)
CO (1) CO6140034A2 (enExample)
CR (2) CR10402A (enExample)
CY (1) CY1110753T1 (enExample)
DE (1) DE602007007473D1 (enExample)
DK (1) DK2021336T3 (enExample)
EA (1) EA015106B1 (enExample)
EC (1) ECSP088833A (enExample)
ES (1) ES2345792T3 (enExample)
HR (1) HRP20100397T1 (enExample)
IL (1) IL194810A (enExample)
MA (1) MA30686B1 (enExample)
MX (1) MX2008013649A (enExample)
MY (1) MY148079A (enExample)
NO (1) NO20084318L (enExample)
NZ (1) NZ571176A (enExample)
PL (1) PL2021336T3 (enExample)
PT (1) PT2021336E (enExample)
RS (1) RS51450B (enExample)
SI (1) SI2021336T1 (enExample)
TN (1) TNSN08417A1 (enExample)
UA (1) UA94741C2 (enExample)
WO (1) WO2007127688A2 (enExample)
ZA (1) ZA200808687B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101055576B1 (ko) * 2006-04-21 2011-08-08 일라이 릴리 앤드 캄파니 11-베타-히드록시스테로이드 데히드로게나제 1의 억제제로서의 시클로헥실피라졸-락탐 유도체
BRPI0710273A2 (pt) 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
JP5265521B2 (ja) 2006-04-21 2013-08-14 イーライ リリー アンド カンパニー １１−β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤としてのビフェニルアミドラクタム誘導体
PL2049475T3 (pl) 2006-04-24 2012-08-31 Lilly Co Eli Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
WO2007127693A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2016071B1 (en) * 2006-04-25 2013-07-24 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
ATE455110T1 (de) 2006-04-25 2010-01-15 Lilly Co Eli 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
DK2035379T3 (da) 2006-04-25 2010-09-06 Lilly Co Eli Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
PT2049513E (pt) * 2006-04-28 2012-03-20 Lilly Co Eli Pirrolidinonas substituídas com piperidinilo como inibidores de 11-beta-hidroxiesteróide desidrogenase i
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
TWI822716B (zh) * 2017-12-21 2023-11-21 大陸商廣東眾生睿創生物科技有限公司 作為ppar促效劑的吡咯啶衍生物的非晶形及其製備方法
CN110483514B (zh) 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
CN110724142B (zh) * 2019-10-29 2022-09-02 启元生物(杭州)有限公司 一种作为jak激酶抑制剂的酰胺或磺酰胺取代的肼衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
ES2525319T3 (es) * 2004-05-07 2014-12-22 Janssen Pharmaceutica Nv Derivados de pirrolidin-2-ona y piperidin-2-ona como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa
MXPA06012929A (es) * 2004-05-07 2007-01-26 Janssen Pharmaceutica Nv Derivados de adamantil pirrolidin-2-ona como inhibidores de 11-beta hidroxiesteroide deshidrogenasa.
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2006049952A1 (en) 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TWI400239B (zh) 2004-11-10 2013-07-01 Incyte Corp 內醯胺化合物及其作為醫藥品之用途
ES2308602T3 (es) * 2004-12-20 2008-12-01 Eli Lilly And Company Derivados de cicloalquil lactamas como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa 1.
WO2006068991A1 (en) 2004-12-21 2006-06-29 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP1864971A4 (en) 2005-03-31 2010-02-10 Takeda Pharmaceutical PROPHYLACTIC / THERAPEUTIC AGENT AGAINST DIABETES
WO2007066921A1 (en) * 2005-12-08 2007-06-14 Ho Young Lee Structure of sticking extraneous matter and warm foot digital compression plate
WO2007084314A2 (en) 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
JP5265521B2 (ja) * 2006-04-21 2013-08-14 イーライ リリー アンド カンパニー １１−β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤としてのビフェニルアミドラクタム誘導体
KR101055576B1 (ko) * 2006-04-21 2011-08-08 일라이 릴리 앤드 캄파니 11-베타-히드록시스테로이드 데히드로게나제 1의 억제제로서의 시클로헥실피라졸-락탐 유도체
BRPI0710273A2 (pt) * 2006-04-21 2011-08-09 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, intermediário
PL2049475T3 (pl) * 2006-04-24 2012-08-31 Lilly Co Eli Pirolidynony podstawione cykloheksylem jako inhibitory 11-betahydrokysterydu dehydrogenazy 1
WO2007127693A1 (en) 2006-04-24 2007-11-08 Eli Lilly And Company Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2016071B1 (en) * 2006-04-25 2013-07-24 Eli Lilly And Company Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
DK2035379T3 (da) * 2006-04-25 2010-09-06 Lilly Co Eli Inhibitorer af 11-beta-hydroxysteroiddehydrogenase 1
ATE455110T1 (de) * 2006-04-25 2010-01-15 Lilly Co Eli 11-beta-hydroxysteroid-dehydrogenase-1-hemmer
PT2049513E (pt) 2006-04-28 2012-03-20 Lilly Co Eli Pirrolidinonas substituídas com piperidinilo como inibidores de 11-beta-hidroxiesteróide desidrogenase i
US20090008890A1 (en) * 2007-06-13 2009-01-08 Woodford James R Suspension system for an all-terrain vehicle
CL2008001839A1 (es) 2007-06-21 2009-01-16 Incyte Holdings Corp Compuestos derivados de 2,7-diazaespirociclos, inhibidores de 11-beta hidroxil esteroide deshidrogenasa tipo 1; composicion farmaceutica que comprende a dichos compuestos; utiles para tratar la obesidad, diabetes, intolerancia a la glucosa, diabetes tipo ii, entre otras enfermedades.
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof

Also Published As

Publication number Publication date
DK2021336T3 (da) 2010-09-13
CN101432275A (zh) 2009-05-13
WO2007127688A2 (en) 2007-11-08
CN101432275B (zh) 2013-10-30
KR101059614B1 (ko) 2011-08-25
EP2021336A2 (en) 2009-02-11
CR10401A (es) 2009-01-14
MX2008013649A (es) 2008-11-04
NZ571176A (en) 2011-10-28
JP2009534468A (ja) 2009-09-24
KR20090034797A (ko) 2009-04-08
US20090111809A1 (en) 2009-04-30
IL194810A (en) 2012-12-31
ES2345792T3 (es) 2010-10-01
CA2646624A1 (en) 2007-11-08
RS51450B (sr) 2011-04-30
TNSN08417A1 (en) 2010-04-14
ATE472542T1 (de) 2010-07-15
US8153807B2 (en) 2012-04-10
WO2007127688A3 (en) 2007-12-21
ECSP088833A (es) 2008-11-27
EA015106B1 (ru) 2011-06-30
CR10402A (es) 2009-07-13
CA2646624C (en) 2013-08-06
HK1126208A1 (en) 2009-08-28
NO20084318L (no) 2008-10-15
ZA200808687B (en) 2010-01-27
IL194810A0 (en) 2009-09-22
UA94741C2 (en) 2011-06-10
MA30686B1 (fr) 2009-09-01
SI2021336T1 (sl) 2010-11-30
HRP20100397T1 (hr) 2010-09-30
AU2007244955A1 (en) 2007-11-08
DE602007007473D1 (en) 2010-08-12
PT2021336E (pt) 2010-07-19
CO6140034A2 (es) 2010-03-19
EP2021336B1 (en) 2010-06-30
CY1110753T1 (el) 2015-06-10
EA200870470A1 (ru) 2009-04-28
PL2021336T3 (pl) 2010-11-30
JP5269765B2 (ja) 2013-08-21
MY148079A (en) 2013-02-28
BRPI0710467A2 (pt) 2011-08-16

Similar Documents

Publication Publication Date Title
AU2007244955B2 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2649650C (en) Substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244742B2 (en) Pieridinyl substituted pyrrolidinones as inhibitors of 11-Beta-hydroxysteroid dehydrogenase 1
AU2007244863B2 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2648236C (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
CA2646678C (en) Cyclohexylimidazole lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007240550B2 (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244971B2 (en) Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
AU2007244861B2 (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
HK1126208B (en) Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired